000127042 001__ 127042
000127042 005__ 20240731103411.0
000127042 0247_ $$2doi$$a10.3389/fmed.2023.1191026
000127042 0248_ $$2sideral$$a134404
000127042 037__ $$aART-2023-134404
000127042 041__ $$aeng
000127042 100__ $$0(orcid)0000-0001-6650-8294$$aMateo-Gallego, Rocio$$uUniversidad de Zaragoza
000127042 245__ $$aThe impact of the COVID-19 pandemic in diabetes and dyslipidemia management in a Spanish region: a retrospective study of the Aragon population
000127042 260__ $$c2023
000127042 5060_ $$aAccess copy available to the general public$$fUnrestricted
000127042 5203_ $$aIntroductionPrevious research has indicated that the COVID-19 outbreak had a negative impact on the diagnosis and management of cardiometabolic diseases. Our aim was to analyze the impact of the COVID-19 pandemic on the management of dyslipidemia and type 2 diabetes (T2D) in the Aragon region of Spain.MethodsWe conducted an observational retrospective study, which included data from all patients diagnosed with active T2D or dyslipidemia in Aragon during 2019–2021. Data was collected from the BIGAN platform, a big database that includes all healthcare data from the Aragon population. Clinical, biochemical, and pharmacological prescription information was obtained for each patient and for each year.ResultsOut of the total population of 1,330,000 in the Aragon region, 90,000 subjects were diagnosed with T2D each year, resulting in a prevalence of approximately 7%. The COVID-19 pandemic resulted in a decrease in the prevalence of this disease and a lower incidence during the year 2020. In addition, patients with T2D experienced a deterioration of their glucose profile, which led to an increase in the number of patients requiring pharmacological therapy. The prevalence of dyslipidemia was approximately 23.5% in both 2019 and 2020 and increased to 24.5% in 2021. Despite the worsening of the anthropometric profile, the lipid profile improved significantly throughout 2020 and 2021 compared to 2019. Moreover, the number of active pharmacological prescriptions increased significantly in 2021.DiscussionOur findings suggest that the overload of the health system caused by the COVID-19 pandemic has resulted in an underdiagnosis of T2D. Moreover, patients with T2D experienced a worsening of their glycemic profile, an increase in their pharmacological requirements, and lower performance of their analytical determinations. Dyslipidemic subjects improved their lipid profile although the value of lipid profile determination decreased between 2020 and 2021.
000127042 536__ $$9info:eu-repo/grantAgreement/ES/DGA/B14-7R
000127042 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000127042 590__ $$a3.1$$b2023
000127042 592__ $$a0.909$$b2023
000127042 591__ $$aMEDICINE, GENERAL & INTERNAL$$b56 / 325 = 0.172$$c2023$$dQ1$$eT1
000127042 593__ $$aMedicine (miscellaneous)$$c2023$$dQ1
000127042 594__ $$a5.1$$b2023
000127042 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000127042 700__ $$aGracia-Rubio, Irene$$uUniversidad de Zaragoza
000127042 700__ $$0(orcid)0000-0001-7098-2327$$aGarza, María Carmen$$uUniversidad de Zaragoza
000127042 700__ $$0(orcid)0000-0002-3312-7759$$aCebollada, Alberto
000127042 700__ $$0(orcid)0000-0002-1894-1621$$aPérez-Calahorra, Sofía$$uUniversidad de Zaragoza
000127042 700__ $$aBayona-Sánchez, Ana
000127042 700__ $$aBujeda-Hernández, Cristina
000127042 700__ $$0(orcid)0000-0001-9142-0737$$aJarauta, Estibaliz$$uUniversidad de Zaragoza
000127042 700__ $$0(orcid)0000-0001-8756-114X$$aSánchez-Calavera, Maria Antonia$$uUniversidad de Zaragoza
000127042 700__ $$0(orcid)0000-0002-9647-0108$$aLamiquiz-Moneo, Itziar$$uUniversidad de Zaragoza
000127042 7102_ $$11006$$2255$$aUniversidad de Zaragoza$$bDpto. Fisiatría y Enfermería$$cÁrea Enfermería
000127042 7102_ $$11003$$2027$$aUniversidad de Zaragoza$$bDpto. Anatom.Histolog.Humanas$$cArea Anatom.Embriol.Humana
000127042 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000127042 773__ $$g10 (2023), 1191026 [9 pp.]$$pFront. med.$$tFrontiers in Medicine$$x2296-858X
000127042 8564_ $$s448069$$uhttps://zaguan.unizar.es/record/127042/files/texto_completo.pdf$$yVersión publicada
000127042 8564_ $$s2288008$$uhttps://zaguan.unizar.es/record/127042/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000127042 909CO $$ooai:zaguan.unizar.es:127042$$particulos$$pdriver
000127042 951__ $$a2024-07-31-10:04:14
000127042 980__ $$aARTICLE